The expression of various miRNAs was modulated (e.g., miR-34c-3p and miR-195-5p were downregulated) in trastuzumab-resistant breast cancer cells and in the plasma of trastuzumab-resistant cancer patients, which led to significantly increased MYB levels[120]. This evidence concerns the gene MYB and breast carcinoma.